Evidence map›Paper›PMID 29191582›Full record

ArticleLung cancer (Amsterdam, Netherlands)2017

Patterns of care and survival among patients with malignant mesothelioma in the United States.

Lindsey Enewold, Elad Sharon, Anish Thomas

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Malignant pleural mesothelioma: an update.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021
    Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Mesothelioma and Social Security Benefits in Brazil: 2019 to 2021.Revista brasileira de medicina do trabalho : publicacao oficial da Associacao Nacional de Medicina do Trabalho-ANAMT
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lindsey EnewoldNational Cancer Institute, Bethesda, MD, United States. Electronic address: lindsey.enewold@nih.gov.
Elad SharonNational Cancer Institute, Bethesda, MD, United States.
Anish ThomasNational Cancer Institute, Bethesda, MD, United States.
National Cancer Institute · US

Funding

Intramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261201000024CNCI NIH HHS HHSN261201000025CNCI NIH HHS HHSN261201000026CNCI NIH HHS HHSN261201000027CNCI NIH HHS HHSN261201000028CNCI NIH HHS HHSN261201000029CNCI NIH HHS HHSN261201000030CNCI NIH HHS HHSN261201000031CNCI NIH HHS HHSN261201000032CNCI NIH HHS HHSN261201000033CNCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000037CNCI NIH HHS HHSN261201000140C
6 · The paper itself

Abstract

backgroundMesothelioma is a rare malignancy that is associated with poor survival. This study aimed to describe the patterns of care and subsequent survival among malignant mesothelioma patients in the United States, while adjusting for patient demographics and comorbidities.

methodsA random sample of patients diagnosed with histologically confirmed mesothelioma in 2011, as reported to the National Cancer Institute's Surveillance Epidemiology and End Results program, were included. Logistic regression and Cox proportional hazard regression were utilized to identify factors associated with receipt of therapy and all-cause mortality, respectively, among patients with pleural mesothelioma.

resultsThis study included 389 patients with pleural mesothelioma and 53 patients with non-pleural mesothelioma. Almost a third (29.3%) of the pleural patients and 21.5% of the non-pleural patients received no therapy. Additionally, approximately 60% of both patient groups received systemic therapy. Among pleural mesothelioma patients, receipt of therapy was less likely among older patients. Median survival was 9 months among the pleural patients and 18 months among the non-pleural patients. Receipt of either surgery or systemic therapy and particularly the combination of these two modalities was associated with better all-cause survival. Additionally, among pleural mesothelioma patients, younger age and lower socioeconomic status were found to be associated with better all-cause survival. Comorbidity score was not found to be associated with receipt of treatment nor was it independently associated with survival among pleural mesothelioma patients.

conclusionThese findings indicate the need for efforts to ensure equitable application of currently available therapies to all patients.

Indexed as

Practice Patterns, Physicians'AdultAgedAged, 80 and overCause of DeathCombined Modality TherapyComorbidityFemaleHealth Care SurveysHumansKaplan-Meier EstimateLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedMesotheliomaPleuralSEERSurvivalTreatment

Identifiers

PMID29191582
PMCPMC5726440
OpenAlexW2745276752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.